Pharmacologic treatment of portal hypertension in the prevention of community-acquired spontaneous bacterial peritonitis

Eur J Gastroenterol Hepatol. 2006 Jan;18(1):49-55. doi: 10.1097/00042737-200601000-00009.

Abstract

Introduction: Given that beta-blockers reduce the incidence of bacterial translocation in cirrhotic rats, the aim of this study was to compare the long-term incidence of spontaneous bacterial peritonitis in cirrhotic patients submitted to pharmacologic versus endoscopic treatment to prevent variceal rebleeding.

Patients and methods: Two hundred and thirty patients with variceal hemorrhage were included in two previous randomized trials performed to compare the efficacy of medication (nadolol plus isosorbide mononitrate, n=115) versus endoscopic treatment (n=115) with sclerotherapy or ligation for the prevention of rebleeding.

Results: The mean follow-up was 23+/-1.4 months. The characteristics of the patients and the number of patients on long-term prophylaxis with norfloxacin were similar in both groups. The incidence of spontaneous bacterial peritonitis was lower in the medication group (9 versus 14.7%, P=NS). The probability of spontaneous bacterial peritonitis was also lower in the medication group (6 versus 12% at 1 year, 22 versus 36% at 5 years; P=0.08), due to a significantly lower probability of community-acquired spontaneous bacterial peritonitis in this group (1 versus 10% at 1 year, 18 versus 32% at 5 years; P=0.02). Patients with no hemodynamic response to therapy had a significantly higher probability to develop community-acquired spontaneous bacterial peritonitis during follow-up than hemodynamic responders (P<0.03). Long-term probability of developing community-acquired spontaneous bacterial peritonitis is lower in patients submitted to pharmacologic treatment for preventing variceal rebleeding than in those submitted to endoscopic treatment.

Conclusion: Long-term pharmacologic prophylaxis of variceal rebleeding contributes to the prevention of community-acquired spontaneous bacterial peritonitis.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Bacterial Infections / etiology
  • Bacterial Infections / prevention & control*
  • Community-Acquired Infections / etiology
  • Community-Acquired Infections / prevention & control
  • Drug Therapy, Combination
  • Epidemiologic Methods
  • Esophageal and Gastric Varices / complications
  • Esophageal and Gastric Varices / drug therapy*
  • Esophageal and Gastric Varices / therapy
  • Esophagoscopy
  • Female
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / prevention & control*
  • Hemodynamics
  • Humans
  • Hypertension, Portal / complications
  • Hypertension, Portal / drug therapy*
  • Hypertension, Portal / therapy
  • Isosorbide Dinitrate / analogs & derivatives
  • Isosorbide Dinitrate / therapeutic use
  • Ligation / methods
  • Male
  • Middle Aged
  • Nadolol / therapeutic use
  • Peritonitis / etiology
  • Peritonitis / prevention & control*
  • Sclerotherapy
  • Secondary Prevention
  • Vasodilator Agents / therapeutic use

Substances

  • Adrenergic beta-Antagonists
  • Vasodilator Agents
  • Nadolol
  • Isosorbide Dinitrate
  • isosorbide-5-mononitrate